The determination of the safety of Chinese medicine for cancer care remains a priority.27 RBC, HGB, WBC, NE#, AST, ALT, LDH, CK, Cr, and BUN were tested in this study with no significant differences between the two groups at the baseline and day 21 (p > 0.05). The gene discussed is CYGB; the disease is cancer.